1. Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia
- Author
-
Arthur Imbach, H. Greigert, Christelle Mausservey, Nadine Magy-Bertrand, Laurent Voillat, Bernard Bonnotte, Guillaume Mourey, Sethi Ouandji, Sylvain Audia, Eric Deconinck, Maxime Samson, Thibault Ghesquière, Denis Caillot, Nicolas Falvo, Jean-Baptiste Picque, and Thomas Rogier
- Subjects
IVIg ,Phagocytosis ,lcsh:Medicine ,030204 cardiovascular system & hematology ,Article ,03 medical and health sciences ,antiplatelet antibodies ,0302 clinical medicine ,hemic and lymphatic diseases ,medicine ,Platelet ,Receptor ,030304 developmental biology ,Autoimmune disease ,chemistry.chemical_classification ,0303 health sciences ,biology ,business.industry ,lcsh:R ,Autoantibody ,General Medicine ,medicine.disease ,chemistry ,Mechanism of action ,immune thrombocytopenia ,Immunology ,biology.protein ,Antibody ,medicine.symptom ,Glycoprotein ,business ,circulatory and respiratory physiology - Abstract
Immune thrombocytopenia (ITP) is a rare autoimmune disease due to autoantibodies targeting platelet glycoproteins (GP). The mechanism of platelet destruction could differ depending on the specificity of antiplatelet antibodies: anti-GPIIb/IIIa antibodies lead to phagocytosis by splenic macrophages, in a Fc&gamma, receptor (Fc&gamma, R)-dependent manner while anti-GPIb/IX antibodies induce platelet desialylation leading to their destruction by hepatocytes after binding to the Ashwell&ndash, Morell receptor, in a Fc&gamma, R-independent manner. Considering the Fc&gamma, R-dependent mechanism of action of intravenous immunoglobulins (IVIg), we assumed that the response to IVIg could be less efficient in the presence of anti-GPIb/IX antibodies. We conducted a multicentric, retrospective study including all adult ITP patients treated with IVIg who had antiplatelet antibodies detected between January 2013 and October 2017. Among the 609 identified, 69 patients were included: 17 had anti-GPIb/IX antibodies and 33 had anti-GPIIb/IIIa antibodies. The response to IVIg was not different between the patients with or without anti-GPIb/IX (88.2% vs. 73.1%). The response to IVIg was better in the case of newly diagnosed ITP (odds ratio (OR) = 5.4 (1.2&ndash, 24.7)) and in presence of anti-GPIIb/IIIa (OR = 4.82 (1.08&ndash, 21.5)), while secondary ITP had a poor response (OR = 0.1 (0.02&ndash, 0.64)). In clinical practice, the determination of antiplatelet antibodies is therefore of little value to predict the response to IVIg.
- Published
- 2020